{
    "name": "simeprevir",
    "comment": "Discontinued",
    "other_names": [
        "Olysio"
    ],
    "classes": [
        "Hepatitis B/Hepatitis C Agents",
        "HCV Protease Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/olysio-simeprevir-999875",
    "pregnancy": {
        "common": [
            "Simeprevir is coadministered with ribavirin and peginterferon alfa; extreme caution must be taken to avoid pregnancy in female patients and female partners of male patients while taking this combination (see Contraindications)",
            "Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin; and therefore ribavirin is contraindicated",
            "Women of childbearing potential and their male partners should not receive ribavirin unless they are using effective contraception (2 reliable forms) during treatment with ribavirin and for 6 months after treatment",
            "Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and female partners of male patients; patients must have a negative pregnancy test prior to therapy; use 2 or more forms of contraception, 1 of these forms of contraception can be a combined oral contraceptive product containing at least 1 mg of norethindrone (lower doses of norethindrone and other forms of hormonal contraception have not been studied or are contraindicated)"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk; because of the potential for adverse reaction, breastfeeding is not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with HCV direct acting antivirals (DDAs)",
                "HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with DDAs and were not receiving HBV antiviral therapy",
                "Some cases have resulted in fulminant hepatitis, hepatic failure, and death",
                "Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up",
                "Initiate appropriate patient management for HBV infection as clinically indicated"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Also consider contraindications to peginterferon alfa and ribavirin",
                "Because ribavirin may cause birth defects and fetal death, simeprevir in combination with peginterferon alfa and ribavirin is contraindicated in pregnant women and in men whose female partners are pregnant"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hepatitis B virus (HBV) reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV DDAs, and who were not receiving HBV antiviral therapy; HBV reactivation is characterized as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level (see Black Box Warnings and Dosing Considerations)",
                "Serious symptomatic bradycardia in patients taking amiodarone with sofosbuvir in combination with simeprevir reported, especially in patients receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease; coadministration of amiodarone with simeprever in combination with sofosbuvir not recommended; in patients without alternative treatment options, cardiac monitoring is recommended",
                "Hepatic decompensation and hepatic failure, including fatal cases, reported when coadministered with peginterferon alfa and ribavirin or in combination with sofosbuvir; most cases were reported in patients with advanced and/or decompensated cirrhosis who are at increased risk for hepatic decompensation or hepatic failure; monitor liver chemistry tests before and during simeprevir combination therapy",
                "Photosensitivity reported, including serious reactions which resulted in hospitalization",
                "Rash may occur, most frequently within the first 4 weeks; mild-to-moderate rashes should be followed for possible progression of rash, including the development of mucosal signs (eg, oral lesions, conjunctivitis) or systemic symptoms; discontinue if rash becomes severe",
                "Contains a sulfonamide moiety; in subjects with a history of sulfa allergy (n=16), no increased incidence of rash or photosensitivity reactions was observed; however, insufficient data exist",
                "Must NOT be used as monotherapy"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Avoid coadministering with moderate or strong CYP3A inhibitors; simeprevir AUC increased >7-fold",
                        "Avoid coadministering with moderate or strong CYP3A inducers; simeprevir trough levels decreased >90%"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole increases levels of simeprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "berotralstat",
            "description": {
                "common": "simeprevir increases levels of berotralstat by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Reduced berotralstat dose to 110 mg/day when coadministered with P-gp inhibitors."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Rash",
            "percent": "28"
        },
        {
            "name": "including photosensitivity",
            "percent": "1"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "27"
        },
        {
            "name": "grade",
            "percent": "22"
        },
        {
            "name": "Pruritus",
            "percent": "22"
        },
        {
            "name": "Nausea",
            "percent": "2"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "18"
        },
        {
            "name": "grade",
            "percent": "16"
        },
        {
            "name": "Myalgia",
            "percent": "12"
        },
        {
            "name": "Dyspnea",
            "percent": "3"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "4"
        },
        {
            "name": "grade",
            "percent": "1"
        },
        {
            "name": "Alkaline phosphatase elevation",
            "percent": "3"
        },
        {
            "name": "grade",
            "percent": "4"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "2"
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Alkaline phosphatase elevation",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Serious symptomatic bradycardia",
            "percent": null
        },
        {
            "name": "patients taking amiodarone who initiate treatment with sofosbuvir in combination with another HCV direct acting antiviral",
            "percent": null
        },
        {
            "name": "including simeprevir",
            "percent": null
        },
        {
            "name": "Hepatic decompensation and hepatic failure",
            "percent": null
        },
        {
            "name": "including fatal cases reported in patients receiving therapy in combination with peginterferon alfa and ribavirin or in combination with sofosbuvir",
            "percent": null
        }
    ]
}